JDD August Issue Highlights | Special Focus: Psoriasis
The August issue of the Journal of Drugs in Dermatology (JDD) focuses on Psoriasis and features mix of original articles, editorials, and case reports. Among many of the topics explored in this issue are treatment of scalp psoriasis, nail psoriasis, respiratory tract infections in patients using biologics for hidradenitis suppurativa, classification of actinic keratosis, lichen planus pigmentosus …
The August issue of the Journal of Drugs in Dermatology (JDD) focuses on Psoriasis and features mix of original articles, editorials, and case reports. Among many of the topics explored in this issue are treatment of scalp psoriasis, nail psoriasis, respiratory tract infections in patients using biologics for hidradenitis suppurativa, classification of actinic keratosis, lichen planus pigmentosus … Continue reading "JDD August Issue Highlights | Special Focus: Psoriasis"
Our new series, “The Many Faces of”, showcases side-by-side images of some of the most commonly seen dermatology conditions in an array of skin tones and briefly highlight nuances in clinical presentation. All images featured in the series are part of The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, a resource developed by co-editors Misty Eleryan, MD, MS, and Adam Friedman, … 
Botulinum toxin is a safe and potentially effective treatment alternative in hidradenitis suppurativa (HS) patients who are resistant to standard therapies, according to the authors of a systematic review published in the Journal of Drugs in Dermatology.
How does this review add to the conversation about new treatments for HS? In which HS patients might dermatologists consider botulinum toxin as … 
Dermatologists are prescribing oral glucocorticoids for psoriasis despite awareness of risks of life-threatening generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). A recent survey of dermatologists published in the Journal of Drugs in Dermatology found 18% of respondents occasionally prescribe oral glucocorticoids to patients with psoriasis, typically 1-5% of the time. Those wh … 
Dr. Lawrence F. Eichenfield, meeting co-chair for the 17th Annual Women’s and Pediatric Dermatology Seminar, kicked off session III with a superb talk titled “Scaling the Heights…and Below, Pediatric Scaling Diseases: Psoriasis and Others”, giving us a bird’s eye view on the old and the new regarding pediatric psoriasis.
Dr. Eichenfield is a complete rock star and served as a valued … 